Assessing the population health impact of market interventions to improve access to antiretroviral treatment

Health Policy and Planning

Volumn 27, Issue 6, 2012, Pages 467-476

  Bärnighausen, Till ^a,b   Kyle, Margaret ^c,d   Salomon, Joshua A ^a   Waning, Brenda ^e,f,g  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KWAZULU NATAL   (South Africa)

^c TOULOUSE SCHOOL OF ECONOMICS   (France)

^d CEPR   (United Kingdom)

^e UNITAID   (Switzerland)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Antiretroviral treatment; assessment; market intervention

Indexed keywords

ANTIRETROVIRUS AGENT;

ARTICLE; ECONOMICS; HEALTH CARE DELIVERY; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; ORGANIZATION AND MANAGEMENT;

ANTI-RETROVIRAL AGENTS; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMANS; POPULATION SURVEILLANCE;

EID: 84865710126     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czr058     Document Type: Article

References (37)

1. Bärnighausen T. 2007. Access to antiretroviral treatment in the developing world: a framework, review and health systems research agenda. Therapy 4: 753-66.
2. Bärnighausen T, Bloom DE. 2009. 'Conditional scholarships' for HIV/AIDS health workers: educating and retaining the workforce to provide antiretroviral treatment in sub-Saharan Africa. Social Science & Medicine 68: 544-51.
3. Bärnighausen T, Bloom DE, Humair S. 2007. Human resources for treating HIV/AIDS: needs, capacities, and gaps. AIDS Patient Care and STDS 21: 799-812.
4. Bärnighausen T, Bloom DE, Humair S. 2010. Universal antiretroviral treatment: the challenge of human resources. Bulletin of the World Health Organization 88: 951-2.
5. Biglan A, Ary D, Wagenaar AC. 2000. The value of interrupted time-series experiments for community intervention research. Prevention Science 1: 31-49.
6. Chaudhuri S, Goldberg PK, Jia P. 2006. Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India. American Economic Review December: 1477-513.
7. Chen RR, Roundy RO, Zhang RQ, Janakiraman G. 2005. Efficient auction mechanisms for supply chain procurement. Management Science 51: 467-82.
8. Deaton A. 2009. Instruments of development: randomization in the tropics, and the search for the elusive keys to economic development. Princeton: Princeton University, Center for Health and Wellbeing.
9. Feachem RG, Sabot OJ. 2006. An examination of the Global Fund at 5 years. The Lancet 368: 537-40.
10. Feachem R, Sabot O. 2007. The Global Fund 2001-2006: a review of the evidence. Global Public Health 2: 325-41.
11. GHT Coalation. 2010. Current and proposed incentive mechanisms. 10 October 2010. Online at: http://www.ghtcoalition.org/files/GHTC-Incentive- Mechanisms-List.pdf (last accessed 26 August 2011).
12. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. 2009. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. The Lancet 373: 48-57.
13. Groenewald P, Bradshaw D, Dorrington R et al. 2005. Identifying deaths from AIDS in South Africa: an update. AIDS 19: 744-5.
14. Hecht R, Bollinger L, Stover J et al. 2009a. Critical choices in financing the response to the global HIV/AIDS pandemic. Health Affairs (Millwood) 28: 1591-605.
15. Hecht R, Wilson P, Palriwala A. 2009b. Improving health R&D financing for developing countries: a menu of innovative policy options. Health Affairs (Millwood) 28: 974-85.
16. Hemphill TA. 2010. Pharmaceutical patent expropriation and technology strategy: strategic options to compulsory licensing. Technology Analysis & Strategic Management 22: 19-41.
17. Herbst AJ, Cooke GS, Bärnighausen T et al. 2009. Adult mortality and antiretroviral treatment roll-out in rural KwaZulu-Natal, South Africa. Bulletin of the World Health Organization 87: 754-62.
18. Herrling P. 2008. Making drugs accessible for poor populations: a funding model. Global Forum Update on Research for Health 5: 152-5.
19. Honig P, Lalonde R. 2010. The economics of drug development: a grim reality and a role for clinical pharmacology. Clinical Pharmacology and Therapeutics 87: 247-51.
20. Kates J, Lief E, Avila C. 2009. Financing the response to AIDS in low-and middle income countries: international assistance from the G8, European commission and other donor governments in 2008. July 2009, The Kaiser Foundation and UNAIDS. Online at: http://data.unaids.org/pub/Presentation/2009/20090704- UNAIDS-KFF-G8-CHARTPACK-2009-en.pdf (last accessed 26 August 2011).
21. Lehmann U, Van Damme W, Barten F, Sanders D. 2009. Task shifting: the answer to the human resources crisis in Africa? Human Resources for Health 7: 49.
22. Lima VD, Johnston K, Hogg RS et al. 2008. Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. Journal of Infectious Diseases 198: 59-67.
23. Mathers CD, Fat DM, Inoue M, Rao C, Lopez AD. 2005. Counting the dead and what they died from: an assessment of the global status of cause of death data. Bulletin of the World Health Organization 83: 171-7.
24. Naegelen F. 2002. Implementing optimal procurement auctions with exogenous quality. Review of Economic Design 7: 135-53.
25. Ngués J. 1993. Social costs and benefits of introducing patent protection for pharmaceutical drugs in developing countries. The Developing Economies XXXI: 24-53.
26. Noehrenberg E. 2010. Implications of patent pools on innovation regarding antiretrovirals. The Open AIDS Journal 4: 67-9.
27. Reichman JH. 2009. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options. Journal of Law, Medicine & Ethics 37: 247-63.
28. Shumbusho F, van Griensven J, Lowrance D et al. 2009. Task shifting for scale-up of HIV care: evaluation of nurse-centered antiretroviral treatment at rural health centers in Rwanda. PLoS Medicine 6: e1000163.
29. Stover J, Bollinger L, Hecht R, Williams C, Roca E. 2007. The impact of an AIDS vaccine in developing countries: a new model and initial results. Health Affairs (Millwood) 26: 1147-58.
30. The Global Fund to Fight AIDS, Tuberculosis and Malaria. 2010. Donors commit US$11.7 billion to the global fund for next three years. Press release, 5 October 2010. Online at: http://www.theglobalfund.org/en/ pressreleases/?pr¼pr-101005c (last accessed 26 August 2011).
31. Vives X. 1999. Oligopoly Pricing. Cambridge, MA: MIT Press.
32. Waning B, Kaplan W, King AC et al. 2009. Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases. Bulletin of the World Health Organization 87: 520-8.
33. Waning B, Diedrichsen E, Moon S. 2010a. A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. Journal of the International AIDS Society 13: 35.
34. Waning B, Kyle M, Diedrichsen E et al. 2010b. Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets. Global Health 6: 9.
35. WHO. 2010. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach, 2010 revision. Geneva: World Health Organization.
36. WHO/UNICEF/UNAIDS. 2010. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. Geneva: World Health Organization.
37. Zachariah R, Ford N, Philips M et al. 2009. Task shifting in HIV/AIDS: opportunities, challenges and proposed actions for sub-Saharan Africa. Transactions of the Royal Society of Tropical Medicine & Hygiene 103: 549-58.